Altimmune, Inc. (ALT)Â
NASDAQ$5.92
Market Cap
$455.92M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
327 of 924
Rank in Industry
190 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
ALT Insider Trading Activity
ALT Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $51,996 | 1 | 50 |
Sells | $110,547 | 1 | 50 |
Related Transactions
| WEAVER GREGORY L | Chief Financial Officer | 1 | $51,996 | 0 | $0 | $51,996 |
| Drutz David | director | 0 | $0 | 1 | $110,547 | $-110,547 |
About Altimmune, Inc.
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Insider Activity of Altimmune, Inc.
Over the last 12 months, insiders at Altimmune, Inc. have bought $51,996 and sold $110,547 worth of Altimmune, Inc. stock.
On average, over the past 5 years, insiders at Altimmune, Inc. have bought $5.73M and sold $897,547 worth of stock each year.
Highest buying activity among insiders over the last 12 months: WEAVER GREGORY L (Chief Financial Officer) — $51,996.
The last purchase of 10,000 shares for transaction amount of $51,996 was made by WEAVER GREGORY L (Chief Financial Officer) on 2025‑03‑13.
List of Insider Buy and Sell Transactions, Altimmune, Inc.
| 2025-03-13 | WEAVER GREGORY L | Chief Financial Officer | 10,000 0.013% | $5.20 | $51,996 | +13.85% | ||
| 2024-08-19 | Sale | Drutz David | director | 16,011 0.0206% | $6.90 | $110,547 | -8.55% | |
| 2023-08-15 | Drutz David | director | 300 0.0006% | $2.88 | $863 | +145.20% | ||
| 2023-03-24 | Eisenstadt Richard I | Chief Financial Officer | 10,000 0.0213% | $4.31 | $43,140 | -5.32% | ||
| 2023-03-23 | Harris Matthew Scott | Chief Medical Officer | 10,000 0.0215% | $4.22 | $42,200 | -2.39% | ||
| 2023-03-23 | Drutz David | director | 9,000 0.0195% | $4.27 | $38,430 | -2.39% | ||
| 2022-12-22 | Sale | Pisano Wayne | director | 20,000 0.0383% | $15.01 | $300,268 | -73.88% | |
| 2022-08-30 | Sale | Garg Vipin K | President and CEO | 20,000 0.0429% | $20.02 | $400,322 | -47.31% | |
| 2022-08-12 | Sale | Garg Vipin K | President and CEO | 15,000 0.0264% | $15.06 | $225,890 | -39.92% | |
| 2022-08-12 | Sale | GILL JOHN | director | 2,714 0.0048% | $15.00 | $40,710 | -39.92% | |
| 2022-07-01 | Sale | Roberts M Scot | Chief Scientific Officer | 10,182 0.022% | $12.00 | $122,184 | +0.62% | |
| 2022-06-29 | Sale | Roberts M Scot | Chief Scientific Officer | 5,462 0.0117% | $12.00 | $65,546 | -3.74% | |
| 2022-06-27 | Sale | Roberts M Scot | Chief Scientific Officer | 37,352 0.0803% | $12.00 | $448,254 | -3.40% | |
| 2022-06-27 | Sale | Jorkasky Diane | 17,610 0.0371% | $11.75 | $206,944 | -3.40% | ||
| 2022-06-15 | Drutz David | 1,000 0.002% | $8.00 | $8,000 | +36.66% | |||
| 2022-05-24 | Drutz David | 1,200 0.0024% | $4.50 | $5,400 | +140.89% | |||
| 2022-02-28 | Sale | Harris Matthew Scott | Chief Medical Officer | 30,000 0.0692% | $7.52 | $225,600 | +52.50% | |
| 2021-03-01 | Sale | Hodges Philip | director | 6,000 0.0151% | $16.08 | $96,480 | -28.09% | |
| 2020-12-10 | Schafer Klaus | director | 2,000 0.0076% | $11.99 | $23,980 | +5.50% | ||
| 2020-12-01 | Sale | Hodges Philip | director | 1,227 0.0047% | $13.54 | $16,614 | -6.30% |
Total: 149
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Drutz David | director | 41958 0.0545% | $248,391.36 | 6 | 1 | +43.65% |
| WEAVER GREGORY L | Chief Financial Officer | 10000 0.013% | $59,200.00 | 1 | 0 | |
| PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | 10 percent owner | 6626403 8.6042% | $39.23M | 1 | 3 | |
| EVNIN LUKE | 10 percent owner | 6347614 8.2422% | $37.58M | 2 | 0 | |
| MPM BIOVENTURES III LLC | 10 percent owner | 6347614 8.2422% | $37.58M | 2 | 0 | |
| Venrock Healthcare Capital Partners III, L.P. | 10 percent owner | 4500000 5.8431% | $26.64M | 4 | 0 | +64.5% |
| VELOCITY PHARMACEUTICAL HOLDINGS LLC | 10 percent owner | 1687250 2.1908% | $9.99M | 0 | 2 | |
| SCHAFFER DERACE L | director | 589453 0.7654% | $3.49M | 41 | 5 | <0.0001% |
| KINLEY MATTHEW P | 541000 0.7025% | $3.2M | 11 | 0 | ||
| WRIGHT DAVID P | President and CEO | 399500 0.5187% | $2.37M | 8 | 0 | |
| PAPPAJOHN JOHN | director | 394044 0.5117% | $2.33M | 15 | 3 | |
| Enright William | President and CEO | 365839 0.475% | $2.17M | 1 | 0 | <0.0001% |
| HEALTHCARE VENTURES VII LP | 10 percent owner | 250000 0.3246% | $1.48M | 1 | 0 | |
| Garg Vipin K | President and CEO | 236797 0.3075% | $1.4M | 1 | 2 | |
| RICHMAN ERIC I | director | 176822 0.2296% | $1.05M | 2 | 3 | |
| Riddle Valerie D | SVP, Medical Director | 44436 0.0577% | $263,061.12 | 0 | 3 | |
| Harris Matthew Scott | Chief Medical Officer | 33311 0.0433% | $197,201.12 | 1 | 2 | <0.0001% |
| SAYARE MITCHEL | director | 32650 0.0424% | $193,288.00 | 2 | 0 | <0.0001% |
| CHANG LINDA L | SVP, CFO & Secretary | 30000 0.039% | $177,600.00 | 1 | 1 | |
| St Peter Steven | director | 25000 0.0325% | $148,000.00 | 1 | 0 | |
| Eisenstadt Richard I | Chief Financial Officer | 22010 0.0286% | $130,299.20 | 1 | 0 | <0.0001% |
| Runge Jeffrey W. | director | 20000 0.026% | $118,400.00 | 2 | 0 | |
| FUERST THOMAS RICHARD | SVP, Chief Scientific Officer | 15000 0.0195% | $88,800.00 | 2 | 0 | |
| Karp Jordan P | SVP, General Counsel | 10000 0.013% | $59,200.00 | 1 | 0 | |
| Schafer Klaus | director | 8900 0.0116% | $52,688.00 | 1 | 1 | +5.5% |
| Hodges Philip | director | 8731 0.0113% | $51,687.52 | 0 | 3 | |
| Pisano Wayne | director | 8498 0.011% | $50,308.16 | 1 | 2 | <0.0001% |
| Roberts M Scot | Chief Scientific Officer | 8305 0.0108% | $49,165.60 | 1 | 3 | <0.0001% |
| GILL JOHN | director | 2771 0.0036% | $16,404.32 | 1 | 2 | <0.0001% |
| Price Kevin | President-Pharmathene UK, Ltd. | 2500 0.0032% | $14,800.00 | 1 | 0 | |
| Jorkasky Diane | 0 0% | $0 | 0 | 1 |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$587,109,125 | 90 | 3.17% | $527.16M | |
$14,527,743 | 76 | 38.40% | $447.93M | |
$84,871,118 | 57 | 17.71% | $412.59M | |
Altimmune, Inc. (ALT) | $24,384,691 | 42 | -30.27% | $455.92M |
$54,828,550 | 26 | -13.88% | $493.09M | |
$26,923,982 | 20 | -17.22% | $407.13M | |
$6,280,187 | 19 | 6.80% | $474.63M | |
$100,566,697 | 18 | -5.10% | $448.11M | |
$124,557,176 | 16 | 29.13% | $513.06M | |
$3,287,638 | 15 | -0.23% | $414.97M | |
$5,338,495 | 12 | 26.45% | $453.88M | |
$92,357,691 | 12 | 87.24% | $469.71M | |
$94,976,497 | 10 | -10.72% | $455.52M | |
$52,263,118 | 10 | -6.89% | $406.76M | |
$1,229,070 | 10 | 23.53% | $487.94M | |
$1,580,951 | 9 | -14.18% | $467.15M | |
$38,624,786 | 9 | 1.26% | $514.33M | |
$602,180 | 4 | -26.17% | $413.61M | |
$3,250,000 | 1 | -44.91% | $482.08M |
ALT Institutional Investors: Active Positions
| Increased Positions | 102 | +58.29% | 5M | +13.58% |
| Decreased Positions | 69 | -39.43% | 4M | -10.63% |
| New Positions | 38 | New | 870,626 | New |
| Sold Out Positions | 24 | Sold Out | 1M | Sold Out |
| Total Postitions | 208 | +18.86% | 41M | +2.95% |
ALT Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Blackrock, Inc. | $40,959.00 | 8% | 6.16M | +693,211 | +12.68% | 2024-12-31 |
| Ameriprise Financial Inc | $34,945.00 | 6.83% | 5.25M | +1M | +35.57% | 2024-12-31 |
| Vanguard Group Inc | $29,470.00 | 5.76% | 4.43M | -552,246 | -11.08% | 2024-12-31 |
| State Street Corp | $23,076.00 | 4.51% | 3.47M | +56,190 | +1.65% | 2024-12-31 |
| Tang Capital Management Llc | $18,288.00 | 3.57% | 2.75M | 0 | 0% | 2024-12-31 |
| Geode Capital Management, Llc | $11,029.00 | 2.15% | 1.66M | -9,498 | -0.57% | 2024-12-31 |
| Knoll Capital Management, Llc | $7,458.00 | 1.46% | 1.12M | 0 | 0% | 2024-12-31 |
| Bellevue Group Ag | $6,287.00 | 1.23% | 945,446 | +81,786 | +9.47% | 2024-12-31 |
| Morgan Stanley | $6,130.00 | 1.2% | 921,822 | -373,763 | -28.85% | 2024-12-31 |
| Ubs Group Ag | $4,785.00 | 0.93% | 719,555 | +437,100 | +154.75% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.